# Pharmacokinetic (PK) Evaluation of Bemotrizinol (6%) in a Sunscreen Maximum Usage Trial

> **NCT05277376** · PHASE3 · COMPLETED · sponsor: **dsm-firmenich Switzerland AG** · enrollment: 162 (actual)

## Conditions studied

- Pharmacokinetics
- Absorption; Chemicals

## Interventions

- **DRUG:** Bemotrizinol (6%)

## Key facts

- **NCT ID:** NCT05277376
- **Lead sponsor:** dsm-firmenich Switzerland AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-15
- **Primary completion:** 2022-10-28
- **Final completion:** 2022-10-28
- **Target enrollment:** 162 (ACTUAL)
- **Last updated:** 2023-02-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05277376

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05277376, "Pharmacokinetic (PK) Evaluation of Bemotrizinol (6%) in a Sunscreen Maximum Usage Trial". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05277376. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*